Date: 2013-11-18
Type of information: Nomination
Compound:
Company: Silence Therapeutics (UK)
Therapeutic area:
Type agreement: nomination resignation
Action mechanism:
Disease:
Details: * On November 18, 2013, Silence Therapeutics announced several changes to the Board of the Company and to its senior management.
Jerry Randall will be stepping down as Executive Chairman of Silence Therapeutics, with immediate effect. He
will be succeeded by Simon Sturge, a current non-executive director of the Company as Chairman, in a nonexecutive
capacity.
The Company also announces the appointment of Dr Alastair Riddell and Dr Stephen Parker as independent
non-executive directors. Dr Alastair Riddell, age 64, has over 30 years of experience in the Pharmaceutical and Biotech industries. Between 2000 and 2010 he was a main board member of the Bioindustry Association of Great Britain. He was chief executive of Stem Cell Sciences plc, 2007 to 2009, Pharmagene plc, 1998 to 2005, and of Paradigm Therapeutics Limited, 2005 to 2007.
Dr Stephen Parker, age 55, is executive chairman of Cantab Biopharmaceuticals and a partner in Celtic
Pharma Holdings Advisors. His career in the healthcare and pharma sector spans over 30 years, including six
in City in advisory roles and two years as finance director of Oxford Glycosciences plc.
The Board Committees will be chaired as follows:
- Remuneration: Alastair Riddell
- Nominations: Simon Sturge
- Audit: Stephen Parker
Management changes: Annie Cheng, previously Director of Corporate Development, is appointed Chief Operating Officer. In her new role she will co-ordinate the work of the commercial team in London with the scientists in Berlin.
Klaus Giese will be retiring from his role as Chief Scientific Officer, to be replaced by Jörg Kaufmann. Jörg was
a co-founder with Klaus of Atugen, the company which became Silence Therapeutics AG.
Silence also announced the strengthening of its Scientific Advisory Board (SAB). The new SAB will work closely with Silence, with each member bringing significant experience and expertise within specialist areas of focus as noted below:
Existing members:
- Professor Detlef Schuppen (University of Mainz) in the field of fibrosis of the liver
- Professor Massimo Pinzani (University College London) in the field of hepatology (focus on liver)
Additional members:
- Dr Trevor Littlewood (University of Cambridge) in the field of oncology
- Dr Sascha David (Hannover Medical School) in the field of acute lung injury
- Professor Justin Stebbing (Imperial College) in the field of oncology
- Professor Gerhard Winter (University of Munich) in the field of chemistry
Financial terms:
Latest news:
